Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
Oluwaseun Falade‐Nwulia(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Jodi B Segal(Johns Hopkins University), Catalina Suarez‐Cuervo(University of North Carolina at Chapel Hill), David R. Nelson(Harvard University Press), Michael Fried(University of North Carolina at Chapel Hill)
Cited by 694
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
|Hepatology|2011|1.1k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|New England Journal of Medicine|2014|907